drugset / Trial / NCT04459611
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-11-01
- Completion
- 2023-07-01
Publications
- Shao M, Yao J, Zhao L, Zhu L, Li B, Li L, Zhou B, Zhang Y, Liu H, Chen X, Wu Z, Chen Z, Fan J, Qiu F. Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial. Cancer Sci. 2026 Jun 7. doi: 10.1111/cas.70442. Online ahead of print.
- Shao M, Yao J, Wang Y, Zhao L, Li B, Li L, Wu Z, Chen Z, Fan J, Qiu F. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial. Signal Transduct Target Ther. 2023 Apr 10;8(1):146. doi: 10.1038/s41392-023-01355-1. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |